Home › Funds › Octagon Capital Advisors LP › DNTH

Octagon Capital Advisors LP position in DNTH

DIANTHUS THERAPEUTICS INC · Health Care

Octagon Capital Advisors LP reported holding 1,686,667 shares of DNTH (DIANTHUS THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$148.5M, representing 19.79% of its reported portfolio and ranking #1 among its reported holdings. Octagon Capital Advisors LP has disclosed DNTH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.69M sh
Reported value held$148.51M
Portfolio Weight19.79%
First reportedQ3 2023
Last changeReduce
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Octagon Capital Advisors LP's DNTH position evolved

Octagon Capital Advisors LP first disclosed a stake in DNTH in Q3 2023 at 480,000 shares (US$6.6M). The position peaked in Q2 2026 at 1,841,667 shares, worth US$179.5M. Across 13 filings, Octagon Capital Advisors LP increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 1,686,667 shares valued at US$148.5M — a reduction of -155,000 shares quarter over quarter.. Notable position changes include a 149% increase in Q1 2024 (shares fell 14% over the following quarter), a 27% increase in Q2 2024 (shares rose 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 480.00K $6.56M New
Q4 2023 554.00K $5.76M Add
Q1 2024 1.38M $41.42M Add
Q2 2024 1.75M $45.20M Add
Q3 2024 1.75M $47.82M Hold
Q4 2024 2.11M $46.00M Add
Q1 2025 2.34M $42.48M Add
Q2 2025 2.34M $43.63M Hold
Q3 2025 2.42M $95.10M Add
Q4 2025 2.42M $99.59M Hold
Q1 2026 1.95M $163.36M Reduce
Q2 2026 1.84M $179.53M Reduce
Q3 2026 1.69M $148.51M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DNTH and 13F data

DNTH (DIANTHUS THERAPEUTICS INC) is a Health Care company. 52 other funds we track also report a position in DNTH — the largest reported positions include Fairmount Funds Management LLC (US$223.4M), Avidity Partners Management LP (US$167.3M), TCG Crossover Management, LLC (US$147.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DNTH

All DNTH fund holders →

FAQ

How long has Octagon Capital Advisors LP held DNTH?

Octagon Capital Advisors LP has disclosed DNTH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Octagon Capital Advisors LP's current position in DNTH?

As of Q3 2026, Octagon Capital Advisors LP holds 1.69M shares of DNTH (DIANTHUS THERAPEUTICS INC), valued at $148.51M, representing 19.79% of its reported portfolio and ranking #1.

Has Octagon Capital Advisors LP been buying or selling DNTH?

In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP reduced its position in DNTH. The position peaked in Q2 2026 at 1.84M shares.

Which other funds hold DNTH?

Other major institutional holders of DNTH include Fairmount Funds Management LLC, Avidity Partners Management LP, TCG Crossover Management, LLC, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.